Islet Sciences, Inc., (ISLT), a biotechnology company engaged in the research, development and commercialisation of patented technologies for people with diabetes, has received the receipt of a Japanese Patent for allowed claims, Patent Application No. 2008-529208.

“This patent is another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community and our stakeholders,” said John Steel, chairman and CEO of Islet Sciences. “We are pleased to announce this significant milestone which clearly strengthens our global value proposition. This patent provides further evidence for the value and promise of this technology to be developed for treatments for diabetes and related complications.”

The notice of allowed claims includes the use and composition for small molecules for prevention or treatment of a pathological inflammatory or autoimmune condition. In particular the pathological conditions include Type 1 diabetes, atherosclerosis, type 2 diabetes, disorders associated with visceral obesity, multiple sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and Alzheimer’s disease.